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Adrenaline in the treatment of anaphylaxis:
what is the evidence?
Andrew P C McLean-Tooke, Claire A Bethune, Ann C Fay, Gavin P Spickett
Adrenaline (epinephrine) is the recommended first line treatment for patients with anaphylaxis. This
review discusses the safety and efficacy of adrenaline in the treatment of anaphylaxis in the light of
currently available evidence. A pragmatic approach to use of adrenaline auto-injectors is suggested.
Anaphylaxis is the clinical syndrome representing the
most severe systemic allergic reactions. Mediator
release results in smooth muscle contraction, vasodila-
tion, increased vascular permeability, and activation of
vagal pathways, leading to the classic features of
anaphylaxis, including urticaria and angioedema,
bronchoconstriction and hypotension. Owing to the
nature of anaphylaxis there are few controlled clinical
trials, and therapeutic recommendations are based on
clinical observation and animal models. We look at the
current evidence for the use of adrenaline (epi-
nephrine) in anaphylaxis, including its safety and route
and timing of administration. We also discuss
adrenaline auto-injectors and their role in patients
with anaphylaxis.
Methods
We searched Medline using the key words adrenaline,
anaphylaxis, epinephrine, and Epipen, and articles
from the authors’ personal collection. When necessary
we accessed cross references and related articles.
Evidence has been graded, where possible (see
bmj.com). Only studies with clinical outcomes have
been classified (see table on bmj.com); those showing
in vitro improvements have not been graded.
Anaphylaxis
Anaphylaxis is a severe, life threatening systemic reac-
tion that can affect all ages. The clinical syndrome may
involve multiple target organs, including skin, respira-
tory, gastrointestinal, and cardiovascular systems. The
essential underlying mechanism is the presence of bio-
logically active chemical mediators released from mast
cells or basophils.1 If this occurs in the context of a
classic IgE mediated reaction from previously sensi-
tised mast cells or basophils then anaphylactic reaction
is the preferred term. Degranulation of mast cells or
basophils may also occur in non-IgE mediated mecha-
nisms, and these reactions are termed anaphylactoid
reactions. Clinically it is not possible to distinguish the
two, and treatments for both mechanisms are identical.
Invalid assumptions of an anaphylactoid cause have
led to fatal re-exposure.2
Anaphylaxis occurs in an acute and unexpected
manner. The true incidence is unknown. Epidemio-
logical studies have shown differing results owing to
differences in both definitions of anaphylaxis and the
population groups studied. A retrospective population
based study in Olmsted County, United States showed
an incidence of 21 cases per 100 000 person years.3 A
retrospective study in a UK accident and emergency
department suggested an incidence of between 1 in
2300 and 1 in 1500 attendances, and retrospective
analysis in a US emergency room has shown an
incidence of 1 in 1100 attendances.4 5 Most data for the
incidence have been derived from hospital databases,
and it is widely believed anaphylaxis is under-
recognised and under-reported.5–7 Anaphylaxis
remains an important cause of mortality. Of 164 fatal
reactions identified between 1992 and 1998 in the
United Kingdom, around half were iatrogenic.8 Of the
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Summary points
Anaphylaxis is a severe life threatening reaction
that can affect all age groups
The severity of previous reactions does not
predict the severity of subsequent reactions
Intramuscular adrenaline is the first line
treatment for anaphylaxis, with intravenous
adrenaline reserved for unresponsive anaphylaxis
or circulatory collapse
Early use of adrenaline in anaphylaxis is
associated with improved outcomes
Any patient with a systemic allergic reaction
should be considered for an adrenaline
auto-injector, depending on risk of further
reactions
There is a clear need to improve education of
both patient and physician on the use of and
indications for adrenaline auto-injectors
See also Primary care
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non-iatrogenic causes, half were related to venom (for
example, wasp sting) and most of the remainder to
food.
Adrenaline has physiological benefits in the
treatment of anaphylaxis: stimulation of  adrenocep-
tors increases peripheral vascular resistance thus
improving blood pressure and coronary perfusion,
reversing peripheral vasodilation, and decreasing
angioedema. Stimulation of 1 adrenoceptors has both
positive inotropic and chronotropic cardiac effects.
Stimulation of 2 receptors causes bronchodilation as
well as increasing intracellular cyclic adenosine mono-
phosphate production in mast cells and basophils,
reducing release of inflammatory mediators.9 However,
given the speed of onset, the often unexpected
occurrence and rapid response to treatment, there are
few controlled clinical trials in acute anaphylaxis, and
this is unlikely to change. Most treatment recommen-
dations have therefore been based on clinical observa-
tion, interpretation of the pathophysiology and, to an
extent, animal models.9 w1
Adrenaline
Is adrenaline safe?
Adrenaline is the recommended first line treatment in
anaphylaxis (fig 1).10 Confusion arises because systemic
allergic reactions can be mild, moderate, or severe. For
example, generalised angioedema and urticaria with-
out airway involvement would not be described as ana-
phylaxis. A good working definition is that an
anaphylactic reaction involves one or both of the two
severe features: respiratory difficulty (which may be
due to laryngeal oedema or asthma) and hypotension
(which may present as fainting, collapse, or loss of con-
sciousness). Inappropriate use of adrenaline may be
dangerous. Most adverse events with adrenaline usage
occur when it is given in overdose or intravenously.
Those particularly at risk include elderly patients and
patients with hypertension, arteriopathies, or known
ischaemic heart disease.7 8 10 w2 w3 As there are no
controlled trials there is no way to estimate the risk in
relation to benefit. Based on the current evidence, the
benefit of using appropriate doses of intramuscular
adrenaline far exceeds the risk (grade C). It should be
stressed that adrenaline is not contraindicated in indi-
viduals with underlying ischaemic heart disease, as the
decrease in filling pressure due to anaphylaxis is likely
to result in further coronary ischaemia (grade C).1
Careful monitoring and avoidance of adrenaline over-
dose is necessary in these patients.
What is the best route for administering
adrenaline?
Subcutaneous and intramuscular routes
The correct route of administration and dose of
adrenaline has been under debate. One study showed
that subcutaneous administration of adrenaline was
associated with a striking difference in the time of
maximum plasma adrenaline concentrations of chil-
dren compared with the intramuscular route (average
time: intramuscular group, 8 minutes; subcutaneous
group, 34 minutes).11 The average maximum plasma
concentration was also significantly higher for the
intramuscular group than for the subcutaneous group,
and this has been shown elsewhere (grade B).11 12
Inhaled adrenaline
Studies using inhaled adrenaline by way of a
pressurised aerosol have given conflicting results.w4-w6
One report showed that adrenaline was present
systemically after an inhaled 3 mg dose but not after
1.5 mg and that the clinical effect was less pronounced
and shorter lasting than by subcutaneous injection.w4
Other studies have shown the reverse.w6 No direct com-
parisons have been made between the inhaled and
intramuscular route. Such findings have only been
shown in healthy volunteers and have, as yet, not been
confirmed in patients during anaphylaxis.
Intravenous route
Intravenous adrenaline has been associated with the
induction of fatal cardiac arrythmias and myocardial
infarction. Major adverse effects usually occur when
adrenaline has been given too rapidly, inadequately
diluted, or in excessive dose (grade C).1 2 8 9 Such
published reports often fail to state clearly that other
factors, including hypoxia, acidosis, or the direct action
of inflammatory mediators, may be, at least in part,
responsible for the cardiovascular complications.
Given all of this, the intravenous route should be
reserved for those with unresponsive anaphylaxis. This
includes any patient who deteriorates despite receiving
intramuscular adrenaline or those in whom there is
doubt about the circulation. It should only be given in
a resuscitation area during electrocardiography by
medical staff who are trained in its use (grade C).7
History of severe allergic type reaction with respiratory
difficulty or hypotension, especially if skin changes present
Oxygen
Repeat in 5 minutes if no clinical improvement
In addition
1. Inhaled β2 agonist such as salbutamol may be used if bronchospasm severe
    and does not respond rapidly to treatment
2. If profound shock immediately life threatening give cardiopulmonary
    resuscitation or advanced life support if necessary. Consider giving adrenaline
    1:10 000 solution slowly intravenously. Hazardous and recommended only for
    experienced physician. Note different strengths used for intramuscular and
    intravenous routes
3. If treated with Epipen, 300 µg will usually be sufficient. A second dose may be
    required. Half doses of adrenaline may be safer for patients taking tricyclic
    antidepressants or β blockers
4. Crystalloid may be safer than a colloid
For all severe or recurrent
reactions and patients with
asthma give hydrocortisone
100-500 mg intramuscularly
or slowly intravenously
If clinical manifestations of shock
do not respond to drug treatment
give 1-2 l of fluid intravenously4
Rapid infusion or one repeat
dose may be necessary
Antihistamine (chlorpheniramine)
10-20 mg intramuscularly or slowly intravenously
Stridor, wheeze, respiratory distress, or clinical signs of shock1
Adrenaline (epinephrine)2,3 1:1000 solution
0.5 ml (500 µg) intramuscularly
Fig 1 Algorithm for the treatment of anaphylaxis. Reproduced with
permission of UK Resuscitation Council
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What dose of adrenaline is appropriate?
Some disagreement exists about the recommended
dose of adrenaline. Although almost all of the
literature agrees on 0.01 mg/kg in infants and
children, North American guidelines suggest a dose in
adults of 0.3-0.5 ml of adrenaline diluted 1:1000
(0.3-0.5 mg), whereas European literature suggests
0.5-1.0 mg.13 w1 w7 No comparative trials have been con-
ducted. For most patients only one dose is needed,
although repeat doses may be given at five minute
intervals until symptoms improve.
Does adrenaline have any important drug
interactions?
Anaphylaxis may be made worse by  blockers, and
these drugs decrease the effectiveness of adrenaline
(grade C).14 Paradoxically the dose of adrenaline
should be halved owing to the increased risks
associated with unopposed stimulation of  adreno-
ceptors and reflex vagotonic effects, including brady-
cardia, hypertension, coronary artery constriction, and
bronchoconstriction.15  Blockers, including eye drops
containing them, should therefore be withdrawn and
substituted in any patient who is considered at risk of
anaphylaxis.16 Tricyclic antidepressants and mono-
amine oxidase inhibitors potentiate adrenaline and
increase the risk of cardiac arrhythmias. The dose of
adrenaline should be halved in these patients (grade
C). Cocaine sensitises the heart to catecholamines (as
does uncontrolled hyperthyroidism), and adrenaline is
therefore relatively contraindicated (grade C).10
When should adrenaline be given?
Evidence in the literature suggests that a poor outcome
from anaphylaxis is associated with late administration
of adrenaline. In a series of 13 fatal and near fatal ana-
phylactic reactions over a 14 month period, only two of
the six patients who died received adrenaline within
the first hour compared with six of the seven survivors
(grade C).17 In a retrospective study of 27 patients with
anaphylaxis occurring outside hospital, all those
treated within 30 minutes recovered compared with
two deaths in those in whom treatment was delayed by
more than 45 minutes (grade C).18 One study showed
that whereas adrenaline was used in the treatment of
62% of fatal reactions it was used in only 14% before
cardiac arrest (grade C).8 This may, however, be due in
some part to both the speed of reactions and the avail-
ability of treatment. As a result current guidelines sug-
gest adrenaline should be given as soon as possible.19
Which patients have the worst outcomes?
The severity of previous reactions does not determine
the severity of future reactions, and subsequent
reactions could be the same, better, or worse. The
unpredictability depends on the degree of allergy and
the dose of allergen.8 20 A series of paediatric
anaphylaxis showed that in two of the three fatal reac-
tions and five of the six near fatal reactions, the previ-
ous allergic event had not required urgent hospital
intervention (grade C).19 Studies have also shown a sig-
nificant increased risk of near fatal and fatal reactions
in patients with coexistent asthma.17 19 In one study, 13
of the 14 fatal or near fatal reactions occurred in
patients with known asthma (grade C). It is not clear if
this is related to the severity of the underlying asthma.
Auto-injectors
Who should be prescribed adrenaline
auto-injectors?
Studies have shown that only 50-75% of patients
prescribed auto-injectors for self administration of
adrenaline carry them around at all times.21–24 w8 Of
these, only 30-40% were able to correctly demonstrate
how they would administer adrenaline to themselves.
A retrospective analysis showed that only 29% of
children with recurrent anaphylaxis were treated with
their adrenaline auto-injector.25 The subsequent need
for adrenaline and admission to hospital was reduced
in those patients who did receive the appropriate dose
by auto-injector (grade C).25 Adrenaline auto-injectors
proved unsuccessful in nine of 14 patients with severe
reactions, either due to unavailability (n = 4), rapidity
of reaction (n = 1), incorrect dose (n = 1), or despite
correct treatment (n = 2) (grade C).8 In another study,
23% (n = 22) of adult patients admitted that they
would probably not be brave enough to self
administer adrenaline—half would seek medical
assistance and the other half would ask another
person.22
Studies in primary and secondary care have shown
that most doctors are themselves uncertain about the
correct method for use of auto-injectors.24 w8 Only
instruction provided by an allergy specialist has been
shown to have any effect on proper injection
technique (grade C).23 24 Patients need to be aware
about expiry dates for their auto-injectors, although
studies have shown adrenaline content and bio-
availabilty in outdated auto-injectors.w9 Instruction by
a physician familiar with auto-injectors and regular
review of technique and reinforcement of the issues
surrounding their use is therefore vital for these
patients (fig 2). Current opinion on prescription of
auto-injectors is divided. American opinion suggests
that all patients with an episode of major allergy
should be prescribed an auto-injector.13 15 In the
United Kingdom some people believe auto-injectors
are over-prescribed.22 Current UK paediatric guide-
lines suggest auto-injectors should be given only to
patients with previous severe reaction or reactions
1. Remove device from carton
2. Remove grey safety cap
3. Place black tip against thigh at 90˚
4. Press hard into thigh until auto-
     injector mechanism functions
     (should click)
Epipen (ALK-Abelló) auto-injector
5. Hold for 10 seconds
6. Massage area for several seconds
7. Discard device safely
1. Remove black needle cap
2. Remove black safety cap
     from red firing button
3. Place against thigh at 90˚
Anapen (Celltech) auto-injector
4. Press red firing button
5. Hold for 10 seconds
6. Massage area for several seconds
7. Discard device safely
Grey safety cap
Black safety cap
Black needle cap
Fig 2 Techniques for use of two auto-injectors
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involving the airway.21 Given that current evidence
supports the relative safety of intramuscular adrena-
line, and early administration is associated with an
improved survival, any patient with a systemic allergic
reaction should be a candidate for adrenaline by
auto-injector. The prescription of auto-injectors,
however, needs to be targeted to those most likely to
use the adrenaline and in whom the benefit outweighs
the risk. We propose an algorithm for identifying
patients who may benefit from an adrenaline
auto-injector (fig 3). Further careful epidemiological
research is needed to clarify who benefits most from
such treatment.
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Is the allergen avoidable?1 Not for auto-injector
Systemic or local reaction?
Systemic reaction
Assess risk
No Yes
Auto-injector x24,5
Low risk High risk3
Local reaction2
History of severe reaction with respiratory difficulty or hypotension
1. No need for adrenaline (epinephrine) if allergen easily avoidable–for example,
    drug reaction
2. Excluding local involvement of the airway, including tongue swelling
3. Patients at high risk are those with asthma; reaction to trace allergen only,
    repeated exposure to allergen likely and lack of access to emergency medical
    care. Comorbidity may alter risk to benefit ratio
4. Patient (or carer) must be capable of understanding the indications for its use
    as well as physically able to use device
5. Consider adjustments to medication if taking β blockers, tricyclic
     antidepressants, or monoamine oxidase inhibitors
Not for auto-injector Auto-injector x24,5
Fig 3 Algorithm for identifying patients who may benefit from an
adrenaline auto-injector
Additional educational resources
Websites
Resuscitation Council UK (www.resus.org.uk/
siteindx.htm)—details current UK resuscuitation
guidelines for anaphylaxis
American Academy of Allergy, Asthma and
Immunology (www.aaaai.org)—good section on
recent literature, with summary and editorial
comment
Joint Council of Allergy, Asthma, and Immunology
(www.jcaai.org/Param/Anaphylax.htm)—provides
guidelines for investigation and management of the
common allergic conditions
British Allergy Foundation
(www.allergyfoundation.com)—source of information
about allergen avoidance
Information for patients
The Anaphylaxis Campaign
(www.anaphylaxis.org.uk)—provides useful information
about anaphylaxis, including practical advice on
avoidance of allergens and support services, as well as
information about adrenaline auto-injectors and
instructions for their use
Endpiece
Fire and ice
Some say the world will end in fire,
Some say in ice.
From what I have tasted of desire,
I hold with those who favour fire.
Robert Frost (1875-1963), American poet
Mark N Lowenthal, internist and geriatrician,
Omer, Israel
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